Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Innovative approaches to enhance regulatory immune cell function and renal transplant survival in nonhuman primates

Award Number: P01AI181829
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2030

Group Awards By:

View Award Description

Innovative approaches to enhance regulatory immune cell function and renal transplant survival in nonhuman primates - OVERALL SUMMARY/ABSTRACT In this P01, we will address the overall hypothesis that innovative regimens incorporating new agents and cutting-edge technologies that selectively enhance regulatory immune cell function, will extend kidney allograft survival and allow immunosuppressive drug withdrawal in rhesus macaques. The candidate regimens will be tested in combination with progressive tapering and withdrawal of conventional immunosuppression (IS). Our hypothesis in Project 1 is that graft survival can be extended and IS withdrawn in MHC-mismatched graft recipients using innovative strategies that selectively enhance inherent dendritic cell (DC) tolerogenicity. These approaches are 1) to target DCs in situ, either with an exciting, novel myeloid cell checkpoint agonist, or with innovative, DC-directed nanobiologics and 2) to adoptively transfer autologous regulatory DCs (DCregs) pulsed with donor-derived small extracellular vesicles (sEVs). Our Specific Aims are: Aim 1: To determine whether the novel myeloid cell checkpoint agonist (anti-LILRB3 mAb) that promotes DC tolerogenicity and allotolerance in mice, can extend graft survival/allow IS withdrawal; Aim 2: To ascertain whether selective targeting of DCs in situ using novel, DC (DEC205)-directed nanobiologics can extend graft survival/allow IS withdrawal; Aim 3: To assess whether infusion of autologous DCregs pulsed with donor-derived immunoregulatory sEVs can extend graft survival/allow IS withdrawal. Our hypothesis in Project 2 is that suppression of innate and adaptive immune mechanisms that would otherwise destabilize induction of tolerance, will be conducive to DCreg and Treg function and consequent prolongation of graft survival/IS withdrawal. We will use new, rhesus-specific mAbs to modulate inflammation, attenuate donor-reactive Tmem and augment donor Ag alloreactive Treg (darTreg); we will also test next generation donor Ag (Bw6)-specific chimeric Ag receptor (CAR)Tregs. Our Specific Aims are: Aim 1:To mitigate post-Tx inflammatory responses and eliminate IS-resistant, donor-reactive pathogenic Tmem through cytokine modulation using new, rhesus-specific neutralizing anti-IL-6 or IL-7R and IL-15R blocking mAbs; Aim 2: To augment Ag-specific Treg through infusion of ex vivo-expanded, genetically- engineered Bw6-specific CARTreg; Aim 3: To achieve durable, donor-alloreactive T cell regulation through CARTreg infusion, combined with either cytokine modulation or in situ targeting of DC, depending on the results of Project 2 Aim 1, and Project 1 Aim 1 and 2 results. Both Projects will incorporate highly-interactive mechanistic studies and assess potential novel biomarkers.The two Projects will be supported by an Administrative, Biostatistics and Bioinformatics Core (Core A), a Transplant Pathology and Tissue Imaging Core (Core B) and a Nanotechnology Core (Core C) and will utilize new agents from the NIAID NHP Reagent Resource. Our Program displays conceptual unity and strong component synergy and incorporates special/unique features of the investigative team and environment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,120,193 )
2026	2026	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	2	6/11/2026	NON-COMPETING CONTINUATION	$2,120,193
														Subtotal = $2,120,193

Issue Date FY: 2025 ( Subtotal = $1,455,073 )
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	1	7/3/2025	NEW	$1,455,073
														Subtotal = $1,455,073

Grand Total All Awards = $3,575,266

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Innovative approaches to enhance regulatory immune cell function and renal transplant survival in nonhuman primates

Award Number: P01AI181829

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer